In the BioHarmony Drug Report Database

"Preview" Icon

Natalizumab

Tysabri (natalizumab) is an antibody pharmaceutical. Natalizumab was first approved as Tysabri on 2004-11-23. It is used to treat crohn disease and multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against integrin alpha-4.

 

Trade Name

 

Tysabri
 

Common Name

 

natalizumab
 

ChEMBL ID

 

CHEMBL1201607
 

Indication

 

crohn disease, multiple sclerosis
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Natalizumab structure rendering